Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA)

Ann Hematol. 2023 May;102(5):1257-1259. doi: 10.1007/s00277-023-05168-8. Epub 2023 Mar 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Humans
  • Imidazoles / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Protein Kinase Inhibitors / adverse effects
  • Pyridazines* / adverse effects
  • Registries

Substances

  • ponatinib
  • Imidazoles
  • Pyridazines
  • Protein Kinase Inhibitors
  • Antineoplastic Agents